1 od parameters, leukocyte depletion, and bone marrow hypoplasia.

2 characterized by peripheral pancytopenia and marrow hypoplasia.

3 asia, extramedullary hematopoiesis, and bone marrow hypoplasia.

4 y reduced BCNU-induced mortality due to bone marrow hypoplasia.

5 eded the development of neutropenia and bone-marrow hypoplasia.

6  (F1) recipients failed to induce the severe marrow hypoplasia and fatal pancytopenia that is produce

7    Here, histology and flow cytometry reveal marrow hypoplasia and impaired hematopoiesis in all coll

8 gnificant thrombocytopenia secondary to both marrow hypoplasia and increased PLT destruction.

9 ich is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effec

10 o, including red blood cell deficiency, bone marrow hypoplasia, and defective thymopoiesis.

11 t in the production of red blood cells, bone marrow hypoplasia, and runting.

12  one of six trials required documentation of marrow hypoplasia before CSF use.

13 M oligoclonal T-cell infiltration and severe marrow hypoplasia indicated by approximately 10-fold dec

14                                              Marrow hypoplasia occurred between days 14 and 28 in 12

15                                              Marrow hypoplasia occurred between days 14 and 28 in 73%

16 res with the development of pancytopenia and marrow hypoplasia, validating a major role for the Fas/F

17                    Overall, postchemotherapy marrow hypoplasia was achieved in 33 patients.

18 hether leukemia response or documentation of marrow hypoplasia was required before cytokine use, and